ArticleWorld journal of surgical oncology2025
DCC-2036 inhibits osteosarcoma via targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Exploring the Tumor Microenvironment in Osteosarcoma: Driver of Resistance and Progression.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOsteosarcoma is a common bone tumor in adolescents and children, characterized by rapid progression, high malignancy, poor prognosis, and a tendency for pulmonary metastasis. Despite extensive research efforts, the specific driver gene associated with osteosarcoma remains unidentified, underscoring the urgent need for novel therapeutic targets and targeted treatment options.
methodsIn vitro studies were conducted to assess the effects of DCC-2036 on the proliferation, migration, and invasion of osteosarcoma (OS) cell lines, employing cloning and Transwell experiments. Network pharmacological analysis, complemented by in vitro experimental validation, indicated the critical target responsible for the inhibitory effects of DCC-2036. RNA sequencing analysis demonstrated that DCC-2036 could induce autophagy in OS cells, with relative protein levels assessed using Western blotting following treatment with the autophagy inhibitor 3-MA and the mTOR agonist MHY1485. In vivo studies further confirmed the role of DCC-2036 in cell proliferation through subcutaneous tumorigenesis.
resultsIn this study, we demonstrated that the small molecule tyrosine kinase inhibitor DCC-2036 effectively inhibited osteosarcoma (OS) cells in both cellular and animal models. We found that DCC-2036 significantly suppressed the proliferation of osteosarcoma cells and induced apoptosis; additionally, it notably inhibited cell migration, invasion, and epithelial-to-mesenchymal transition (EMT). HCK was identified as the key target mediating the effects of DCC-2036 on osteosarcoma. Mechanistically, DCC-2036 was shown to inhibit the expression of phosphorylated AKT (p-AKT), phosphorylated S6 kinase (p-S6K), and phosphorylated 4E-binding protein 1 (p-4EBP1) within the downstream PI3K/AKT/mTORC1 signaling pathway. Furthermore, in vivo experiments utilizing subcutaneous tumor xenografts in mice demonstrated that DCC-2036 effectively inhibited the growth of xenografted 143B cells in BALB/C-nude mice.
conclusionsCollectively, these findings indicate that DCC-2036 promotes autophagy in osteosarcoma (OS) cells by targeting the HCK/AKT/mTORC1 axis and exerts anti-tumor effects without significant toxicity. Consequently, DCC-2036 emerges as a promising therapeutic agent for the treatment of HCK-overexpressing osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.